bimagrumab and tirzepatide Antibody blockade of activin type II receptors preserves skeletal muscle mass enhances fat loss during GLP-1 receptor agonism Bimagrumab: Novel Medical Therapy for
Description
Tirzepatide, with its dual action as both a GLP-1 and GIP receptor agonist, might be more potent at lower doses compared to semaglutide, which acts only on the GLP-1 receptor
Patients are finally experiencing meaningful appetite control and, in many cases, significant weight loss
Adults with obesity on the 15mg maintenance dose lost an average of 22.5% of their body weight over 72 weeks
Includes dosage schedule, side effect management, and lifestyle tips.
Get started at ahara.com and accomplish your weight loss goals today!
Enroll for free.
